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Radiotherapy for pancreatic cancer is limited by the tolerance of local organs at risk OARs and
frequent overlap of the planning target volume PTV and OAR volumes. Using lexicographic
ordering LO, a hierarchical optimization technique, with generalized equivalent uniform dose
gEUD cost functions, we studied the potential of intensity modulated radiation therapy IMRT to
increase the dose to pancreatic tumors and to areas of vascular involvement that preclude surgical
resection surgical boost volume SBV. We compared 15 forward planned three-dimensional
conformal 3DCRT and IMRT treatment plans for locally advanced unresectable pancreatic cancer.
We created IMRT plans optimized using LO with gEUD-based cost functions that account for the
contribution of each part of the resulting inhomogeneous dose distribution. LO-IMRT plans allowed
substantial PTV dose escalation compared with 3DCRT; median increase from 52 Gy to 66 Gy
a=−5, p0.005 and median increase from 50 Gy to 59 Gy a=−15, p0.005. LO-IMRT also
allowed increases to 85 Gy in the SBV, regardless of a value, along with significant dose reductions
in OARs. We conclude that LO-IMRT with gEUD cost functions could allow dose escalation in
pancreas tumors with concomitant reduction in doses to organs at risk as compared with traditional
3DCRT. © 2007 American Association of Physicists in Medicine. DOI: 10.1118/1.2426403
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lexicographic orderingI. INTRODUCTION
Of the estimated 30,000 patients diagnosed annually in the
United States with pancreatic cancer1 only approximately
10% have potentially curable resectable disease. Another 30–
40% have locally advanced disease without detectable me-
tastasis, for which chemoradiotherapy is the standard of care.
Local therapy can provide good palliation and, despite the
high propensity of pancreatic cancer for distant metastases,
radiotherapy may provide a survival advantage.2 Unfortu-
nately, radiotherapy dose is limited by the tolerance of the
organs in the upper abdomen. Thus, current radiation regi-
mens are limited to inadequate tumor doses of only 54 Gy
in 1.8–2.0 Gy per fraction. Results are poor with response
rates of only 10–25%, and a median survival of 8–12
months.3–7 Better regimens are sorely needed for these pa-
tients and radiation dose escalation carries the potential for
improved local control and palliation.
There have been attempts, mostly unsuccessful, of inten-
sification of regimens for unresectable pancreas cancer, both
by combining radiation with more effective chemotherapy,
and with radiation dose escalation. One approach has been to
combine preoperative external beam irradiation with intraop-
erative radiation to reduce dose to the organs at risk. Median
survival times have been 12 months, with a 20% 5 year
survival.5,8–10 Escalation of external beam irradiation has
also been attempted using three-dimensional conformal ra-
521 Med. Phys. 34 „2…, February 2007 0094-2405/2007/34diation therapy 3DCRT to 70–72 Gy in 41 patients.11
However, severe, unacceptable, toxicity including gas-
trointestinal toxicity leading to death in three patients was
encountered.
Tumor invasion into adjacent vessels, most often the ce-
liac and superior mesenteric arteries, makes complete resec-
tion difficult or impossible because the en bloc resection
would require sacrificing the arteries. Patients unable to un-
dergo resection inevitably progress both locally and with dis-
tant metastases. Currently, the only long term survivors of
pancreatic cancer are those with a complete surgical resec-
tion. Patients with partial vein involvement, previously con-
sidered unresectable, who undergo newer surgical resection
with vein grafting, have survival rates comparable to patients
with traditionally operable tumors.12,13 In this study, we have
defined the tumor vascular interface as a planning target vol-
ume PTV subvolume, the surgical boost volume SBV,
with the hypothesis that sterilization of this interface could
convert patients to surgical candidates who could be ex-
pected to have improved clinical outcomes.
The proximity of organs at risk OARs, the duodenum,
small intestine, and stomach, limit conventional external
beam radiation dose to 54 Gy, as planning target volume
PTV and OAR volumes often overlap. Intensity modulated
radiation therapy IMRT, by allowing flexible shaping of
isodose surfaces and selective placement of steeper dose gra-
dients, may allow escalation of effective dose to the whole
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vascular interface that prevent tumor resection.
In principle, relaxing dose homogeneity constraints across
the target can be used to increase the dose delivered to por-
tions of the PTV.14 For any given PTV, dose distributions
could be nonuniformly rearranged in numerous ways, creat-
ing many differing heterogeneous dose distributions. In order
to achieve clinically relevant dose escalation, it would be
useful to characterize the biological significance e.g., in
terms of tumor-cell kill of each of these dose distributions
i.e., evaluate the significance of small cold spots and larger
hot spots within the target volume in terms of predicted clini-
cal outcomes. The generalized equivalent uniform dose
gEUD models the effect of heterogeneous dose distribu-
tions considering the assumed radiosensitivity of the target
tissue.15–17 Investigators have performed gEUD based IMRT
planning studies, for prostate, head and neck, liver, and lung
tumors.18–20
IMRT planning generally requires the use of optimization
techniques, and various multi-criteria optimization strategies
have begun to be applied to inverse planning problems, par-
ticularly when trade-offs between normal tissue and tumor
must be made.21,22 For inverse planning problems in which
the planning goals show distinctive levels of importance,
such as heterogeneous dose escalation for pancreatic tumors
within the context of normal tissue limits, lexicographic or-
dering LO23 provides an intuitive and efficient way of gen-
erating a plan solution. For LO-based optimization, the hier-
archical planning goals are categorized into several levels of
priority. The various priority level goals are optimized se-
quentially, one level of priority at a time, with the least im-
portant planning goals addressed last. By subdividing a large
multi criteria problem into several somewhat smaller prob-
lems based on priority levels, the complex space of trade-offs
can be significantly simplified, greatly decreasing the need
for iterative optimization trials before a solution that satisfies
the goals of the protocol is found.
Here, we combine the use of lexicographic ordering opti-
mization for inverse planned IMRT with gEUD-based cost
functions for PTV dose escalation and dose volume histo-
gram DVH defined dose limits for OARs to test the follow-
ing hypotheses: 1 LO optimized IMRT with gEUD as a
cost function will allow dose escalation to pancreatic tumors
while simultaneously lowering radiation doses to OARs, and
2 gEUD based IMRT will allow simultaneous boosting of
the surgical boost volume SBV, an obstacle to potential
curative resection of pancreatic cancer.
II. MATERIALS AND METHODS
A. Treatment planning
With approval from the University of Michigan Institu-
tional Review Board, we conducted retrospective treatment
planning studies on the data from 15 patients who had un-
dergone 3DCRT for unresectable pancreatic cancer. The
original treatment planning computed tomography CT
scans, with patients receiving dual-phase intravenous con-
trast as well as oral contrast in a fasting state, were used for
Medical Physics, Vol. 34, No. 2, February 2007this study. The gross tumor volume GTV was defined as
the imaged tumor. There was no prophylactic irradiation
planned for the draining lymph node basin, as these patients
were generally treated at our institution using concurrent ad-
ministration of systemic doses of gemcitabine.24 The clinical
target volume was defined as the GTV with a 0.5 cm expan-
sion and an additional 0.5 cm expansion was added to define
the planning treatment volume PTV. Within each GTV, the
area of vascular involvement precluding surgical resection of
the tumor was identified and delineated as a surgical boost
volume SBV. The SBV was defined with input from expe-
rienced pancreaticoduodenal surgeons and corresponds to the
area that would need to be a tissue plane between unresect-
able vessel and tumor to allow en bloc tumor resection. All
significant OARs were contoured liver, stomach, duodenum,
small intestine, kidneys and spinal cord. Each case had
overlap of one or more OARs with the PTV: stomach in 11,
small intestine in 12, and duodenum in all 15 cases Table I.
1. 3DCRT plans
The 3D plans used for this study were the ones actually
used for the treatment of these patients, and were designed
by experienced clinical dosimetrists. The number and angle
of fields was chosen to avoid OARs, with three fields most
often used. Treatment planning objectives were defined by
the institutional chemoradiation protocols, with the 54 Gy
95% isodose surface encompassing 99.5% or more of the
PTV.
2. IMRT plans
For each case, an IMRT plan was also generated using six
noncoplanar beams, with 0.5 cm beamlets applied to each
beam to cover the PTV. Angles were similar to those re-
ported previously.25 Lexicographic ordering optimization of
26–28
TABLE I. Overlap of organs at risk cases.
Case
Stomach
overlaps PTV
Duodenum
overlaps PTV
Small intestine
overlaps PTV
1 x x x
2 x x x
3 x x
4 x x
5 x x
6 x x x
7 x x x
8 x x x
9 x x x
10 x x x
11 x x
12 x x
13 x x x
14 x x
15 x x
Total % 11 73% 15 100% 12 80%treatment plans was performed using UMPlan/UMOpt,
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In UMOpt, IMRT optimization is performed based on doses,
Dv, calculated by
Dv = 
j=1
n
Tj,v j , 1
where  j represents the fluence intensity for jth beamlet
among a total of n beamlets or n optimization variables and
Tj,v is a predetermined coefficient matrix that quantifies dose
contributions from the jth beamlet with unity intensity to
dose calculation points in the region of interest, v. UMOpt
utilizes a wide range of planning metrics.29 Specifically in
this study, planning criteria for the OAR and normal tissues
are achieved by minimizing objective functions consisting of
DVH or Lyman30 normal tissue complication probability
NTCP metrics while target dose escalations are performed
using gEUD15–17 as a planning metric
gEUD =  1
m

i=1
m
di
a 1a 2
for m-dose points in a volume of interest v; the correspond-
ing doses diDv 0 im; and tissue-specific parameter
a. A general structure of objective functions follows nonlin-
ear least-square problem representation:31
For the OAR and normal tissues,
f = HPDv −  2. 3
For the target structures,
f = H− PDv2, 4
where H is the Heaviside unit step function; PDv repre-
sents a planning metric determined from the regional dose,
Dv e.g., gEUD, NTCP, or mean dose; and finally  is a
constant value specified as a desired achievement level for a
given planning criterion. DVH criteria are modeled as sug-
gested by Bortfeld32 and Wu.33
In this study, the LO-based planning solves three optimi-
zation problems sequentially in order of importance, i.e.,
three priority levels of optimization. Each problem is con-
structed by a linear combination of objective functions that
are categorized as a same priority
F = 
k
fk . 5
Before each subsequent level of optimization, the objective
functions from the prior level are converted to individual
inequality constraints with boundaries set by the optimized
results27
fk fk* 6
for all k in a given priority level, where
* = arg min F . 7
Consequently, the achievements for the important plan-
ning criteria are preserved while pursuing less important cri-
teria in lower levels.
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in both objective functions and constraints requires to solve
nonlinearly constrained optimization problems. For these
problems, UMOpt uses a Sequential Quadratic Programming
SQP algorithm31,34 which is a well-established constrained
optimization method exhibiting a high performance for
large-scaled problems with significant nonlinearity. In SQP,
search directions are generated by solving convex quadratic
subproblems. A line search method is used to ensure the SQP
method converges from remote starting positions by enforc-
ing a sufficient decrease of an augmented Lagrangian func-
tion. Exact Jacobians are computed using an Automatic Dif-
ferentiation algorithm27 and Hessians are estimated by a
Broyden-Fletcher-Goldfarb-Shanno-reduced algorithm.31 For
all results shown in this study, optimizations always con-
verged to optimality, resulting in both optimal and feasible
solutions.
IMRT planning for all tumors is represented by gEUD
with negative a values, with variation depending on the
grade or aggressiveness of the individual tumor.15–19 If
a=−, the gEUD is equal to the minimal tumor dose, repre-
senting a very aggressive tumor in which tumor control will
be adversely affected by even the smallest cold spot. When
the biologic behavior of tumors is more benign, the a values
can be adjusted to be correspondingly less negative. In this
study, a values of −15 and −5 were used. Optimization con-
straints were placed to ensure that the maximal tolerated
doses to the spinal cord, kidneys, stomach, duodenum, liver,
and small intestine were not exceeded in all cases Table II.
In this study, the OAR dose goals were identified as the most
important, therefore addressed at the first level in LO. After
these dose limits were ensured, escalation of the PTV dose
was pursued at the second level. The goals were to maximize
the minimum target dose, maximize the target gEUD, and
keep maximum target dose 90 Gy. Escalation of dose over
90 Gy in small subvolumes was felt to be, most likely, clini-
cally not important. Finally, a general goal of dose reduction
in all normal tissues was pursued at the third level.
B. End points and statistical analysis
To evaluate the magnitude of dose escalation which might
be possible, the gEUD values for the PTV and SBV were
TABLE II. Dose constraints for organs at risk.
OARa Dose constrains using 1.8 Gy fractions
Duodenum 60 Gy maximum, with no more than 33%45 Gy.
Stomach 54 Gy maximum, with no more than 2%50 Gy, and
no more than 25%45 Gy.
Small intestine 54 Gy maximum, with no more than 2%50 Gy, and
no more than 25%45 Gy.
Liver minimize NTCPb using parameters for 1.8 Gy fx
Kidneys 20 Gy maximum, no more than 10%18 Gy, minimize
overall
Spinal cord 45 Gy maximum, minimize overall
aOARorgans at risk.
bNTCPnormal tissue complication probability.recalculated with a values of −15 and −5 for each plan re-
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fect of dose escalation on the normal organs at risk, for both
the IMRT and 3DCRT plans the equivalent uniform dose of
each was calculated using a values of 6 and 10, consistent
with the range of published values.19,35,36 A paired t test was
used to test differences between means for significance. In
order to determine if IMRT dose escalation was inversely
correlated with target volumes, a Pearson correlation regres-
sion analysis was done, as shown in Table III.
TABLE III. Target volumes cm3 and EUD Gy achieved with dose
escalation.
Case
Volume
PTV
a=−5
EUD PTV
a=−15
EUD PTV
Volume
SBV
a=−5
EUD SBV
a=−15
EUD SBV
1 112 72 63 8 89 88
2 240 60 54 40 66 58
3 193 58 52 13 87 86
4 282 67 60 25 89 89
5 151 67 58 20 87 87
6 162 68 60 18 89 88
7 313 69 59 38 85 84
8 145 74 64 12 88 87
9 415 60 54 9 88 88
10 195 60 54 11 84 84
11 287 67 60 22 90 90
12 176 66 59 10 88 88
13 135 66 59 15 82 77
14 344 64 57 35 81 79
15 406 75 68 23 87 87
R2 0.1 0.1 0.37 0.34Medical Physics, Vol. 34, No. 2, February 2007III. RESULTS
An example IMRT plan obtained with LO optimization is
provided in Fig. 1. In this patient, the stomach, duodenum,
and small intestine all overlap with the PTV. A noncoplanar
arrangement of 6 IMRT fields 0.5 cm beamlets was used to
produce steep dose gradients in the overlap region. DVHs of
the 3DCRT and IMRT plans illustrate that the IMRT plan
results in higher PTV doses and lower OAR doses.
The potential improvement in delivered dose using IMRT
with lexicographic ordering did require some additional time
following structure definition over 3DCRT. The 3DCRT
plans took approximately one half hour to plan and compute
dose for templated beam arrangement, although selection of
appropriate noncoplanar beam arrangements37,38 could often
take up to two or three times as much time. Generation of an
IMRT plan with lexicographic ordering took approximately
twice as long, primarily due to the initial dose to points cal-
culation offline. However, the increase in planning time
with LO-IMRT was much less than what we previously ex-
perienced with our more conventional IMRT optimization
approaches.
The resultant dose increases in the PTVs with the current
approach are not confined to small subvolumes. Figure 2A
describes the average proportion of the PTV above 54, 70.2,
75, and 80 Gy, respectively. Nearly all cases had greater than
90% of the PTV above 54 Gy, average 91±7.5%, with
47±16% above 75 Gy, and 35±15% above 80 Gy. The
mean gEUD achieved with LO IMRT and 3DCRT for the 15
cases is shown in Fig. 2B for two a values, −5 66±5 Gy
FIG. 1. Representative plan and DVH.
A Abdominal CT demonstrating the
surgical boost volume, SBV red con-
tour, defined as a specific boost re-
gion within the PTV pink contour.
B An example plan showing six-field
noncoplanar IMRT beamlet intensity
maps. Structures: PTV is pink, SBV is
red, duodenum is yellow, small intes-
tine is tan, stomach is green, kidneys
are blue, and liver is brown. C Axial
CT slice demonstrating OAR and PTV,
along with a temperature scale trans-
parent isodose colorwash. D Dose-
volume histogram for case in 1C
planned both with IMRT solid lines
and 3DCRT dashed lines.
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P0.005. The increased PTV gEUD did not correlate with
size of the PTV, as shown in Table III.
The dose escalation to the PTV provided by the IMRT
plans did not result in increased doses to normal tissues in
close proximity to the PTV Fig. 3. For these normal tissue
EUD calculations a parameter values of 6 and 10 were used;
values are considered representative of the tissue tolerance of
gastrointestinal organs.39–41 LO optimized IMRT resulted in
a significant decrease in gEUD for both a values for all three
organs duodenum, small intestine, stomach. For the duode-
num, the 3DCRT doses were 47±1 a=6, and 48±1 a
=10, compared with IMRT doses of 41±1 a=6, P
0.005, and 46±1 a=10, P0.05. For the small intes-
tine, the 3DCRT doses were 37±2 a=6, and 41±1 a
=10, compared with IMRT doses of 21±2 a=6, P
0.005, and 33±2 a=10, P0.005. For the stomach, the
3DCRT doses were 34±2 a=6, and 39±2 a=10, com-
pared with IMRT doses of 25±3 a=6, P0.005, and
31±3 a=10, P0.005.
The simultaneous boosting of the SBV resulted in an av-
erage gEUD in the vascular interface of 85 Gy, regardless of
a value 85±5 Gy for a=−5 and 85±8 Gy for a=−15,
FIG. 2. EUD optimized IMRT PTV dose escalation. A Mean percentage of
PTV above 54, 70.2, 75, and 80 Gy  the standard deviation. B Mean
EUD ± standard deviation for the PTV for 15 pancreas cancer cases using
LO optimized IMRT using EUD cost functions white or 3DCRT black.
For an a=−5 radiosensitive tumor, and for an a=−15 radioresistant tu-
mor. An ** indicates P0.005.Fig. 4.
Medical Physics, Vol. 34, No. 2, February 2007IV. DISCUSSION
In the current study, we investigated the possibility of
escalating the effective radiation dose to the tumor in locally
advanced unresectable pancreatic cancers by creating non-
uniform target volume dose distributions using lexicographic
ordering optimized IMRT with gEUD as a cost function.
Although all cases had significant overlap of OAR with PTV,
significant dose escalation was achievable compared to the
current 3DCRT standard. As shown in Fig. 2A, moderate
increases in effective dose to the whole PTV were possible in
most cases and substantial increases in dose to large fractions
of the PTV were possible in all cases. These increases in
dose were independent of tumor size.
By relaxing constraints on tumor dose homogeneity, ad-
ditional dose may be delivered to PTV subvolumes that do
not overlap the local organs at risk. Although the significance
FIG. 3. Equivalent uniform dose optimized IMRT decreases dose to organs
at risk. Average doses 15 cases ± standard error to organs at risk during
radiation delivery to pancreas cancer duodenum, small intestine, and stom-
ach for 3DCRT black bars and LO-IMRT white bars computed for two
values for normal tissue, 6 and 10. An * indicates p0.05, and ** indicates
p0.005 for 3DCRT vs IMRT.of selectively boosting tumor subvolumes to higher doses is
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tumor control probability.42,43 We elected to use gEUD in the
cost function within the optimizing process because this
model takes into account the potential contribution to tumor
control of all parts of the dose-volume distribution, based on
the presumed tumor radiosensitivity. Therefore, we feel this
represents a rational method to drive the process of dose
escalation and may provide biologically optimal dose distri-
butions. As would be expected, we also found that unlimited
heterogeneity in the PTV does not increase the gEUD sig-
nificantly data not shown. Depositing high doses in minute
volumes would not be expected to contribute to tumor con-
trol probability. However, rearranging the dose to selectively
boost regions of higher tumor burden or a tumor subvolume
for in this case, see more below the potential of making the
patient a surgical candidate remain worthy goals.
To assess the biologic significance of the heterogeneous
dose distribution achieved, an estimate of the tumor radi-
osensitivity is required. We chose to evaluate this with two
values of a, −5 and −15. Unfortunately, the “a” values of
both normal tissue and tumor are approximations. To over-
come this limitation we have used values that cover the
range of what is currently thought to represent the a value for
the tissues studied. In this gEUD model, negative numbers of
larger magnitude indicate increasing radioresistance. Given
that pancreas tumors clinically have a poor response rate, and
based on published preclinical data generated with pancreatic
cancer cell lines and xerographs, it is likely that an a value of
−15 more accurately represents pancreas tumors. Although
our results indicate that the magnitude of gain was greater in
radiosensitive tumors, substantial dose escalation was pos-
sible even under the assumption of extreme radioresistance.
For a=−15 the mean PTV gEUD increased from 50 to 59, an
increase representing at least three fractions more than cur-
FIG. 4. Dose escalation to resection limiting volume RLV. Resulting mean
RLV EUD values 15 cases, ± standard error of the mean, for a=−5 radi-
osensitive and a=−15 radioresistant tumors.rently achievable.
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crease in dose delivered to normal tissues. In computing
gEUD in normal tissues, we have used a values within the
established range 6–14 for the normal tissues
concerned.18,19 Our findings are in agreement with a previous
report showing reduction in normal tissue doses in the treat-
ment of pancreatic tumors with IMRT.44 Although it is likely
that such reduction would translate into a reduction in toxic-
ity, the impact of cytotoxic chemotherapy or biological
agents, commonly used concurrently with radiotherapy in
this disease, is hard to predict. It is possible that the use of
such agents would negate some of the expected gains. A
clinical trial will be needed to evaluate the clinical impact of
our approach on toxicities and on local control. It is worth
noting that in this work we minimized doses to OARs using
cost functions with DVH dose constraints. Although this re-
sulted in substantial reductions in dose to OARs, it is pos-
sible that further gains may be realized by use of gEUD-
based constraints for normal tissues.
Due to the poor outcome in the treatment of pancreatic
cancer with radiation therapy,3–7 further information on the
dose response of pancreatic cancer would be helpful. Unfor-
tunately, the data directly addressing this issue are sparse.
The use of 54 Gy in conventionally fractionated radiation
produces responses from 10–25% with concurrent 5-FU or
gemcitabine based chemotherapy. There have been a few re-
cent studies intensifying therapy with different radiation dose
regimens. Tsujie et al.45 demonstrated a 35% partial response
rate with 1.5 Gy twice daily fractions to 45 Gy with concur-
rent 5-FU and cisplatin chemotherapy. Hypofractionated ra-
diation with five 3 Gy fractions per week combined with
concurrent 5-FU resulted in a partial response in three of
eight patients.46 Stereotactic radiation therapy by Hoyer et
al.47 with three 15 Gy fractions resulted in a 9% response
rate. Rich et al.48 showed the addition of paclitaxel to
50.4 Gy in 1.8 Gy fractions resulted in a 32% response rate
in a multi-institutional phase II trial. However, it appears that
these different regimens have not produced clearly superior
results to concurrent gemcitabine and radiation. To our
knowledge, there have been no formal studies of radiation
dose response in pancreatic cancer patients. We hope that the
application of optimization strategies such as those presented
here will enable studies that will enhance our understanding
of the dose response of pancreatic cancer.
In this study we have ignored the dosimetric conse-
quences of organ motion, and we have used a fixed 1 cm
expansion from GTV to PTV, which may not account fully
for pancreatic tumor motion.49–51 We have taken this ap-
proach since this has been the guideline in all University of
Michigan pancreas clinical trials over the past decade, and
has been the de facto clinical standard at our institution. Any
future clinical application of this algorithm would have to
address both target and normal tissue motion and shape
change. Accounting for organ motion and shape change with
respiration and digestion remains a technical challenge in the
clinical delivery of IMRT to the abdomen.49 Intra-fraction
reproducibility can be improved with active breathing
52 53
control. Additionally, online imaging and implanted
527 Spalding et al.: Pancreas cancer IMRT optimization 527markers51,54 can improve set up error to improve interfrac-
tion target localization. We are currently conducting a study
measuring pancreas motion and deformation, to specifically
determine how to account for target localization for IMRT
delivery. Only with safe tumor immobilization and localiza-
tion could this technique be implemented.
Clinical implementation of the methodologies described
herein could potentially result in increases in resectability of
borderline-resectable or unresectable tumors. Surgical resec-
tion continues to have the strongest impact on outcome of
patients with pancreatic cancer. Recent advances in surgical
techniques allow resection of tumors with minimal superior
mesenteric vein, inferior vena cava, or hepatic artery
involvement.4,12,13,55 It appears that these more aggressive
vein-resection procedures may extend survival in patients
who would not be considered surgical candidates by conven-
tional standards.55 Similarly, patients with unresectable dis-
ease who are rendered resectable by standard chemoradio-
therapy and undergo surgery appear to have a survival
similar to patients who are surgical candidates at
presentation.56,57 Together, these data suggest that aggressive
local therapy could result in improved local control and sur-
vival.
In this study we have shown that LO optimized IMRT
with gEUD cost functions can deliver dramatically increased
doses to the surgical boost volume, with doses approaching
90 Gy regardless of a value of −5 or −15. It is conceivable
that such dose escalation in the context of a neoadjuvant
regimen could potentially allow more patients to undergo
curative resection by sterilizing the tumor-vascular interface.
Dose escalation to the areas of vascular involvement could
also be associated with additional toxicity. For instance, reir-
radiation of squamous cell carcinoma of the head and neck
has shown that total doses exceeding 100 Gy can lead to
vessel necrosis ranging in 2% to 15% of cases.58 Thus, the
clinical utility of such strategy needs to be evaluated in care-
fully conducted clinical trials.
In summary, this work demonstrates that lexicographic
ordering optimization of IMRT with gEUD-based cost func-
tions for locally advanced pancreatic cancer can allow dose
escalation with decreased dose to organs at risk. Further-
more, simultaneous additional boosting of the tumor subvol-
umes precluding resection, the SBV, is possible. A radiation
dose escalation study in patients with unresectable pancreatic
cancer, using the methodology described herein, is currently
under way at our institution. That study will help evaluate
the potential benefits and toxicity associated with this ap-
proach.
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